Objective:

We evaluated the utility of the Clinical Dementia Rating Sum of Boxes score (CDR-SB) in staging and detecting amnestic-mild cognitive impairment (a-MCI) and Alzheimer’s disease (AD) among Mexican Americans.

Methods:

Receiver operator curves were generated to evaluate the validity of the CDR-SB in staging and detecting a-MCI and AD in 1,073 Mexican Americans (758 controls, 163 a-MCI, and 152 AD).

Results:

Optimal ranges of the CDR-SB were 0, 0.5-4, 4.5-8.0, 8.5-13 and 13.5-18 for staging the global CDR score of 0, 0.5, 1, 2, and 3, respectively. The CDR-SB ≥ 0.5 differentiated the a-MCI patients from the controls (sensitivity 100% and specificity 99.5%) and ≥ 2.0 distinguished the AD from a-MCI patients (sensitivity 83.6% and specificity 87.1%). These cutoffs were also appropriate for patients with ≤6 years of education.

Conclusion:

The CDR-SB is useful to detect and stage a-MCI and AD in Mexican Americans with diverse education levels.

中文翻译：

---

临床痴呆评定量表总和在墨西哥裔美国人认知障碍分期和检测中的有效性

客观的：

我们评估了临床痴呆评分总和 (CDR-SB) 在墨西哥裔美国人中对轻度遗忘型认知障碍 (a-MCI) 和阿尔茨海默病 (AD) 进行分期和检测的效用。

方法：

生成接收操作者曲线以评估 CDR-SB 在 1,073 名墨西哥裔美国人（758 名对照、163 名 a-MCI 和 152 名 AD）中分期和检测 a-MCI 和 AD 的有效性。

结果：

CDR-SB 的最佳范围分别为 0、0.5-4、4.5-8.0、8.5-13 和 13.5-18，用于分期全球 CDR 评分 0、0.5、1、2 和 3。CDR-SB ≥ 0.5 区分了 a-MCI 患者与对照组（敏感性 100% 和特异性 99.5%），≥ 2.0 区分了 AD 与 a-MCI 患者（敏感性 83.6% 和特异性 87.1%）。这些临界值也适用于受教育年限≤6 年的患者。

结论：

CDR-SB 可用于检测和分期具有不同教育水平的墨西哥裔美国人的 a-MCI 和 AD。